Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2215-0838
  • E-ISSN: 2215-0846

Abstract

Background and Objectives

This study aimed to explore the treatment of thrombosis caused by COVID-19 with the drugs used in Unani medicine. Unani medicine has rich literature that mentions the pathogenesis, causes, and treatment of the diseases caused by obstruction of vessels. The study explores various drugs with actions that complement the resulting thrombolytic actions and details the rational treatment plan following the Unani medicine protocol.

Methodology

The literature regarding thrombosis was surveyed from indexed online journals. The concept of thrombosis in Unani literature was surveyed from the source texts of Unani medicine. The treatment strategy and drugs with anti-thrombotic actions were explored, and a rational graded management of thrombosis in COVID-19 patients was presented that forms the general treatment plan of Unani medicine in patients with thrombosis.

Results

The study observed that several Unani drugs from natural sources are mentioned for de-obstruent action. De-obstruent action is a composite action that encompasses anti-inflammatory, disintegratory, blood detoxification, and other activities. There was a concordance with the concept of thrombolytic action, as mentioned in conventional medicine. When rationally used, these drugs form a graded treatment of thrombosis associated with COVID-19.

Conclusion

There is a potentially successful treatment plan with several de-obstruent drugs in Unani medicine that may be explored to treat thrombosis associated with COVID-19.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctm/10.2174/2215083810666230914103404
2023-10-05
2025-09-02

  • From This Site

    /content/journals/ctm/10.2174/2215083810666230914103404
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PitlikS.D. COVID-19 compared to other pandemic diseases.Rambam Maimonides Med. J.2020113e002710.5041/RMMJ.10418 32792043
     [Google Scholar]
  2. SeyedAlinaghi S, Afsahi AM, MohsseniPour M, et al. Late Complications of COVID-19; a systematic review of current evidence.Arch. Acad. Emerg. Med.202191e14 33681819
     [Google Scholar]
  3. CastroR.A. FrishmanW.H. Thrombotic complications of COVID-19 infection: A review.Cardiology20212914347 32947478
     [Google Scholar]
  4. KumarV. AbbasA.K. FaustoN. Robbins, and Cotran Pathologic Basis of Disease.7th edElsevier2004
     [Google Scholar]
  5. BarcoS. BatesS.M. VersteegH.H. KlokF.A. COVID-19 in thrombosis research: An editorial perspective.Thromb. Res.202120114715010.1016/j.thromres.2021.03.011 33798826
     [Google Scholar]
  6. AdamE.H. ZacharowskiK. MiesbachW. A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients.Thromb. Res.2020194424410.1016/j.thromres.2020.06.026 32723615
     [Google Scholar]
  7. ZulkifleM. TaulehaS. SharifZ. Treatment option for COVID-19.J AYUSH20211016
     [Google Scholar]
  8. LeeL.H. GuK.Q. HengD. Deep vein thrombosis is not rare in Asia--the singapore general hospital experience.Ann. Acad. Med. Singap.2002316761764 12520831
     [Google Scholar]
  9. AgarwalaS. BhagwatA.S. ModheJ. Deep vein thrombosis in Indian patients undergoing major lower limb surgery.Indian J. Surg.2003652159162
     [Google Scholar]
  10. RashidiF. BarcoS. KamangarF. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study.Thromb. Res.202119813513810.1016/j.thromres.2020.12.001 33338976
     [Google Scholar]
  11. MaieseA. ManettiA.C. La RussaR. Autopsy findings in COVID-19-related deaths: A literature review.Forensic Sci. Med. Pathol.2020202018 33026628
     [Google Scholar]
  12. CarsanaL. SonzogniA. NasrA. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study.Lancet Infect. Dis.202020101135114010.1016/S1473‑3099(20)30434‑5 32526193
     [Google Scholar]
  13. KapteinF.H.J. StalsM.A.M. GrootenboersM. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave.Thromb. Res.202119914314810.1016/j.thromres.2020.12.019 33535120
     [Google Scholar]
  14. WanY. ShangJ. GrahamR. BaricR.S. LiF. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus.J. Virol.2020947e00127e2010.1128/JVI.00127‑20 31996437
     [Google Scholar]
  15. GheblawiM. WangK. ViveirosA. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: cClebrating the 20th anniversary of the discovery of ACE2.Circ. Res.2020126101456147410.1161/CIRCRESAHA.120.317015 32264791
     [Google Scholar]
  16. MagroneT. MagroneM. JirilloE. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target-a perspective.Endocr. Metab. Immune Disord. Drug Targets2020206807811
     [Google Scholar]
  17. MishraK.P. SinghA.K. SinghS.B. Hyperinflammation and immune response generation in COVID-19.Neuroimmunomodulation2020272808610.1159/000513198 33341814
     [Google Scholar]
  18. KaserA. BrandacherG. SteurerW. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis.Blood20019892720272510.1182/blood.V98.9.2720 11675343
     [Google Scholar]
  19. LefrançaisE. Ortiz-MuñozG. CaudrillierA. The lung is a site of platelet biogenesis and a reservoir for hematopoietic progenitors.Nature20175447648105109
     [Google Scholar]
  20. MohanH. Textbook of Pathology.5th edNew DelhiJAYPEE Brothers200539610.5005/jp/books/10939
     [Google Scholar]
  21. KeserG. DonmezA. KeserG. Inflammation-induced thrombosis: Mechanisms, disease associations and management.Curr. Pharm. Des.201218111478149310.2174/138161212799504731 22364132
     [Google Scholar]
  22. EsmonC.T. Inflammation and thrombosis.J. Thromb. Haemost.2003171343134810.1046/j.1538‑7836.2003.00261.x 12871267
     [Google Scholar]
  23. SpaetheS.M. NeedlemanP. Arachidonic acid metabolism in tissue injury.Cellular and Molecular Aspects of Inflammation.Boston, MASpringer1988153169
     [Google Scholar]
  24. MoncadaS. VaneJ.R. Interrelationships between prostacyclin and thromboxane A2.Ciba Found. Symp.198078165183 6258879
     [Google Scholar]
  25. MontezanoA.C. Nguyen Dinh CatA. RiosF.J. TouyzR.M. Angiotensin II and vascular injury.Curr. Hypertens. Rep.201416643144210.1007/s11906‑014‑0431‑2 24760441
     [Google Scholar]
  26. HeM. HeX. XieQ. ChenF. HeS. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes.Thromb. Res.2006117557959010.1016/j.thromres.2005.04.033 15953627
     [Google Scholar]
  27. JonmarkerS. HollenbergJ. DahlbergM. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.Crit. Care202024165310.1186/s13054‑020‑03375‑7 33225952
     [Google Scholar]
  28. PavoniV. GianeselloL. PazziM. SteraC. MeconiT. FrigieriF.C. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.Thromb. Res.202019631331710.1016/j.thromres.2020.09.013 32977129
     [Google Scholar]
  29. PesaventoR. CeccatoD. PasquettoG. The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience.J. Thromb. Haemost.202018102629263510.1111/jth.15022 32692874
     [Google Scholar]
  30. MusokeN. LoK.B. AlbanoJ. Anticoagulation and bleeding risk in patients with COVID-19.Thromb. Res.202019622723010.1016/j.thromres.2020.08.035 32916565
     [Google Scholar]
  31. KolliasA. KyriakoulisK.G. SyrigosN.K. StergiouG.S. Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?Thromb. Res.2021199192010.1016/j.thromres.2020.12.013 33385796
     [Google Scholar]
  32. HsuA. LiuY. ZayacA.S. OlszewskiA.J. ReaganJ.L. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia.Thromb. Res.202019637537810.1016/j.thromres.2020.09.030 32980620
     [Google Scholar]
  33. CukerA. TsengE.K. NieuwlaatR. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.Blood Adv.20215387288810.1182/bloodadvances.2020003763 33560401
     [Google Scholar]
  34. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2012-1
  35. WHO. Antithrombotic therapy in patients with COVID-19.2023Available from:http://www.covid19treatmentguidelines.nih.gov/antithrombotictherapy
    [Google Scholar]
  36. IbnR. Kitab ul Kulliyat (Urdu translation).New DelhiCCRUM1987
     [Google Scholar]
  37. SenaI. Kulliyat e Qanoon.New DelhiIdara Kitab-ul-Shifa20151
     [Google Scholar]
  38. KabeeruddinM. Kitab al Akhlat.New DelhiCCRUM2009162174
     [Google Scholar]
  39. SenaI. Al Qanoon Fil Tib.New Delhi: Idara Kitab us Shifa2007
     [Google Scholar]
  40. MajoosiA. Kamil us Sana. New Delhi: Idara kitab us shifa 2010; 2nd.
     [Google Scholar]
  41. BaghdadiI.H. Kitab al Mukhtarat fit Tib. volume 1st.New Delhi CCRUM2005129292
     [Google Scholar]
  42. NafeesAB Kulliyat e Nafeesi.New Delhi: Idara Kitab ul Shifa1934
     [Google Scholar]
  43. RaziZ. Kitab al Murshid.New DelhiTaraqi Urdu Bureau2000
     [Google Scholar]
  44. ArzaniA. Tib e Akbar.Deoband: Faisal publication1925
     [Google Scholar]
  45. TabriAHS Firdaus ul Hikmat. New Delhi: Idara kitab ul shifa2017
     [Google Scholar]
  46. KhanA. Akseer-e-aazam (Kabeeruddin M). Idara kitab ul shifa2011
     [Google Scholar]
  47. RaziZ. Kitab al Hawi. New Delhi: CCRUM 2000; 7th.
     [Google Scholar]
  48. Logat e Kabeer. New Delhi: YNM 2000
  49. KhanM.A. Muhet Azam.New DelhiCCRUM2012
     [Google Scholar]
  50. KabeeruddinM. Makhzan ul Mufradat.New Delhi: Idara kitab ul Shifa2014
     [Google Scholar]
  51. RampuriNG khazain ul Advia. New Delhi: Idara kitab ul Shifa2011
     [Google Scholar]
  52. BaitarI. Al Jamiul Mufradat al Advia wa Aghzia (Urdu translation by Indlasi AA).New DelhiCCRUM2000
     [Google Scholar]
  53. BaitarI. Al Jamiul Mufradat al Advia wa Aghzia (Urdu translation by Indlasi AA). New Delhi: CCRUM 2000; 2nd.
     [Google Scholar]
  54. BaitarI. Al Jamiul Mufradat al Advia wa Aghzia (Urdu translation by Indlasi AA). New Delhi: CCRUM 2000; 3rd.
     [Google Scholar]
  55. HarwiMY Ain al Hayat (Urdu translation by Rehman Z). Aligarh Ibn Sena academy 2007
     [Google Scholar]
  56. LakhnawiA.H. Mufradat Azeezi.New DelhiCCRUM2009
     [Google Scholar]
  57. JavadiB. SahebkarA. EmamiS.A. A survey on saffron in major islamic traditional medicine books.Iran. J. Basic Med. Sci.2013161111 23638288
     [Google Scholar]
  58. NematiH. BoskabadyM.H. Ahmadzadef VostakolaeiH. Stimulatory effect of Crocus sativus (saffron) on β2-adrenoceptors of guinea pig tracheal chains.Phytomedicine200815121038104510.1016/j.phymed.2008.07.008 18771905
     [Google Scholar]
  59. NeamatiN. BoskabadyM.H. Effect of Crocus sativus (saffron) on muscarinic receptors of guinea pig tracheal chains.Funct. Plant Sci. Biotechnol.20104128131
     [Google Scholar]
  60. RezaeeR. HosseinzadehH. Safranal: From an aromatic natural product to a rewarding pharmacological agent.Iran. J. Basic Med. Sci.20131611226 23638289
     [Google Scholar]
  61. AjamM. ReyhaniT. RoshanravanV. ZareZ. Increased miscarriage rate in female farmers working in saffron fields: A possible effect of saffron toxicity.Asia Pac. J. Med. Toxicol.2014327375
     [Google Scholar]
  62. BhartiS. GolechhaM. KumariS. SiddiquiK.M. AryaD.S. Akt/GSK-3β/eNOS phosphorylation arbitrates safranal-induced myocardial protection against ischemia–reperfusion injury in rats.Eur. J. Nutr.201251671972710.1007/s00394‑011‑0251‑y 21983875
     [Google Scholar]
  63. GruenwaldJ. FrederJ. ArmbruesterN. Cinnamon and health.Crit. Rev. Food Sci. Nutr.201050982283410.1080/10408390902773052 20924865
     [Google Scholar]
  64. JavedI. FaisalI. RahmanZ. Lipid lowering effect of Cinnamomum zeylanicum in hyperlipidaemic albino rabbits.Pak. J. Pharm. Sci.2012251141147 22186322
     [Google Scholar]
  65. MathewS. AbrahamT.E. Studies on the antioxidant activities of cinnamon (Cinnamomum verum) bark extracts, through various in vitro models.Food Chem.200694452052810.1016/j.foodchem.2004.11.043
     [Google Scholar]
  66. ShahA.H. Al-ShareefA.H. AgeelA.M. QureshiS. Toxicity studies in mice of common spices, Cinnamomum zeylanicum bark and Piper longum fruits.Plant Foods Hum. Nutr.199852323123910.1023/A:1008088323164 9950084
     [Google Scholar]
  67. FathiazadF. HamedeyazdanS. A review on Hyssopus officinalis L.: Composition and biological activities.Afr. J. Pharm. Pharmacol.201151719591966
     [Google Scholar]
  68. KreisW. KaplanM.H. FreemanJ. SunD.K. SarinP.S. Inhibition of HIV replication by Hyssop officinalis extracts.Antiviral Res.199014632333710.1016/0166‑3542(90)90051‑8 1708226
     [Google Scholar]
  69. MilletY. TognettiP. LavairepierlovisiM. SteinmetzM. ArdittiJ. JouglardJ. Étude expérimentale des propriétés toxiques convulsivantes des essences de sauge et d’hysope du commerce.Rev. Electroencephalogr. Neurophysiol. Clin.197991121810.1016/S0370‑4475(79)80047‑7 493616
     [Google Scholar]
  70. MushirA. JahanN. SofiG. Exploration of Unani concept of blood purifying drugs and likely models for its screening.Bangladesh J Med Sci201918231232110.3329/bjms.v18i2.40702
     [Google Scholar]
  71. ShahriarM. IslamS. ParvinS. HoqueS. Thrombolytic activity, and antimicrobial properties of Ficus hispida.J Sci Res20135239339710.3329/jsr.v5i2.11988
     [Google Scholar]
  72. LeeS.E. JuE.M. KimJ.H. Free radical scavenging and antioxidant enzyme fortifying activities of extracts from Smilax China root.Exp. Mol. Med.200133426326810.1038/emm.2001.43 11795490
     [Google Scholar]
  73. KapperaS. MGR D. Antidiabetic and hypolipidemic activity of methanolic extract of Sphaeranthus indicus in alloxan-induced diabetic rats.Indo Am J Pharmaceut Res2014491152185225
     [Google Scholar]
  74. NandaB.K. JenaJ. RathB. BeheraB.R. Analgesic, and antipyretic activity of whole parts of Sphaeranthus indicus Linn.J. Chem. Pharm. Res.200911207212
     [Google Scholar]
  75. RaoC. VermaA. GuptaP. VijayakumarM. Anti-inflammatory and anti-nociceptive activities of Fumaria indica whole plant extract in experimental animals.Acta Pharm.200757449149810.2478/v10007‑007‑0039‑z 18165192
     [Google Scholar]
  76. KabeeruddinM. Bayaz e Kabeer.
     [Google Scholar]
  77. IslasJF AcostaE G-Buentello Z, et al An overview of Neem (Azadirachta indica) and its potential impact on health.J. Funct. Foods20207410417110.1016/j.jff.2020.104171
     [Google Scholar]
  78. AmerH. HelmyW.A. TaieH.A. In vitro antitumor and antiviral activities of seeds and leaves Neem (Azadirachta indica) extracts.Int. J. Acad. Res.2010224751
     [Google Scholar]
  79. JoseR.J. ManuelA. COVID-19 cytokine storm: The interplay between inflammation and coagulation.Lancet Respir. Med.202086e46e4710.1016/S2213‑2600(20)30216‑2 32353251
     [Google Scholar]
  80. NaikM. AgrawalD. BeheraR. BhattacharyaA. DehuryS. KumarS. Study of anti-inflammatory effect of neem seed oil (Azadirachta indica) on infected albino rats.J Health Res Rev2014136610.4103/2394‑2010.153880
     [Google Scholar]
  81. SoaresDG GodinAM MenezesRR Anti-inflammatory and antinociceptive activities of azadirachtin in mice.Planta Med20148008/09630-610.1055/s‑0034‑1368507
     [Google Scholar]
  82. Al-SnafiA.E. Fumaria parviflora-A review.Indo-Am J Pharmaceut Sci20185317281738
     [Google Scholar]
  83. RizviW. FayazuddinM. SinghO. Anti-inflammatory effect of Fumaria parviflora leaves based on TNF-α, IL-1, IL-6 and antioxidant potential.Avicenna J. Phytomed.2017713745 28265545
     [Google Scholar]
  84. KhattakS.G. GilaniS.N. IkramM. Antipyretic studies on some indigenous Pakistani medicinal plants.J. Ethnopharmacol.1985141455110.1016/0378‑8741(85)90027‑3 3878916
     [Google Scholar]
  85. DamleM. Glycyrrhiza glabra (Liquorice)-a potent medicinal herb.Int. J. Herb. Med.201422132136
     [Google Scholar]
  86. JahanY. SiddiquiH.H. Study of antitussive potential of Glycyrrhiza glabra and Adhatoda vasica using a cough model induced by sulfur dioxide gas in mice.Int. J. Pharm. Sci. Res.2012361668
     [Google Scholar]
  87. WolkerstorferA. KurzH. BachhofnerN. SzolarO.H.J. Glycyrrhizin inhibits influenza A virus uptake into the cell.Antiviral Res.200983217117810.1016/j.antiviral.2009.04.012 19416738
     [Google Scholar]
  88. RossumT.G.V. VultoA.G. HopW.C. BrouwerJ.T. NiestersH.G. SchalmS.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double‐blind, randomized, placebo‐controlled phase I/II trial.J. Gastroenterol. Hepatol.199914111093109910.1046/j.1440‑1746.1999.02008.x 10574137
     [Google Scholar]
  89. SasakiH. TakeiM. KobayashiM. PollardR.B. SuzukiF. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients.Pathobiology200270422923610.1159/000069334 12679601
     [Google Scholar]
  90. PompeiR. FloreO. MarccialisM.A. PaniA. LoddoB. Glycyrrhizic acid inhibits virus growth and inactivates virus particles.Nature1979281573368969010.1038/281689a0 233133
     [Google Scholar]
  91. KaurR. KaurH. DhindsaA.S. Glycyrrhiza glabra: A phytopharmacological review.Int. J. Pharm. Sci. Res.2013472470
     [Google Scholar]
  92. PastorinoG. CornaraL. SoaresS. RodriguesF. OliveiraM.B.P.P. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review.Phytother. Res.201832122323233910.1002/ptr.6178 30117204
     [Google Scholar]
  93. RaziZ. Kitab al Hawi.New DelhiCCRUM2000
     [Google Scholar]
  94. RatheeshM. HelenA. Anti-inflammatory activity of Ruta graveolens Linn on carrageenan-induced paw edema in Wistar male rats.Afr. J. Biotechnol.200761012091211
     [Google Scholar]
  95. SaieedP. RezaR.M. AbbasD. SeyyedvaliR. AliasgharH. Inhibitory effects of Ruta graveolens L. extract on guinea pig liver aldehyde oxidase.Chem. Pharm. Bull.200654191310.1248/cpb.54.9 16394541
     [Google Scholar]
  96. de FreitasT.G. AugustoP.M. MontanariT. Effect of Ruta graveolens L. on pregnant mice.Contraception2005711747710.1016/j.contraception.2004.07.014 15639078
     [Google Scholar]
  97. WessnerD. HofmannH. RingJ. Phytophotodermatitis due to Ruta graveolens applied as protection against evil spells.Contact Dermat.199941423210.1111/j.1600‑0536.1999.tb06145.x 10515113
     [Google Scholar]
  98. Arias-SantiagoS.A. Fernández-PugnaireM.A. Almazán-FernándezF.M. Serrano-FalcónC. Serrano-OrtegaS. Phytophotodermatitis due to Ruta graveolens prescribed for fibromyalgia.Rheumatology200948111401140910.1093/rheumatology/kep234 19671699
     [Google Scholar]
  99. PatilR. MohanM. KastureV. KastureS. Rubia cordifolia: A review.Orient. Pharm. Exp. Med.20099111310.3742/OPEM.2009.9.1.001
     [Google Scholar]
  100. JainA. BasalE. Inhibition of Propionibacterium acnes-induced mediators of inflammation by Indian herbs.Phytomedicine2003101343810.1078/094471103321648638 12622461
     [Google Scholar]
  101. PrasadS. KashyapR.S. DeopujariJ.Y. PurohitH.J. TaoriG.M. DaginawalaH.F. Effect of Fagonia arabica (Dhamasa) on in vitro thrombolysis.BMC Complement. Altern. Med.2007713610.1186/1472‑6882‑7‑36 17986325
     [Google Scholar]
  102. GodatwarP.K. ChaudharyS. SharmaR. in vitro thrombolytic activity of Dhamasa (Fagonia arabica Linn.), Kushta (Saussurea lappa Decne.), and Guduchi (Tinospora cordifolia Thunb.).Ayu201536442142410.4103/0974‑8520.190697 27833372
     [Google Scholar]
  103. ChourasiaS.R. KashyapR.S. PurohitH.J. DeopujariJ.Y. TaoriG.M. DaginawalaH.F. In-vitro clot lytic potential of Fagonia arabica: A comparative study of two methods.Blood Coagul. Fibrinolysis201122428829410.1097/MBC.0b013e32834512d8 21427565
     [Google Scholar]
  104. AgeelyH.M. GuptaS.K. LatifM.A. PatilB.R. Review of ethnomedicinal plant Fagonia.Int. J. Pharma Sci.201452228
     [Google Scholar]
  105. AdibaM. JahanN. HussainI.M. Evaluation of the antithrombotic activity.2013Available from:https://www.evms.edu/covid-19/medicalinformationresources/
    [Google Scholar]
/content/journals/ctm/10.2174/2215083810666230914103404
Loading
Unani Approach to Graded Management of Thrombosis in COVID-19 Patients
Current Traditional Medicine 11, E140923221052 (2025); https://doi.org/10.2174/2215083810666230914103404
/content/journals/ctm/10.2174/2215083810666230914103404
/content/journals/ctm/10.2174/2215083810666230914103404
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Anti-thrombotic action; COVID-19 complications; graded management; SARS-CoV-2; thrombosis; Unani drugs

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test